Optimized Treatment of Refractory Hypercholesterolemia in Patients with Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia with Alirocumab (OPTIMIZE)
- DOI
- 10.2139/ssrn.4028503
- Published
- 2022
- Container
- SSRN Electronic Journal
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.2139/ssrn.4028503,
title = {Optimized Treatment of Refractory Hypercholesterolemia in Patients with Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia with Alirocumab (OPTIMIZE)},
author = {Isabella Sudano and François Mach and Tiziano Moccetti and Thilo Burkard and Christian Fahe and Alain Delabays and Hans Rickli and Pierre-Frédéric Keller and Jörn Dopheide and Sereina Bodenmann and Tom Fiolka and Georg Ehret and David Spirk},
year = {2022},
journal = {SSRN Electronic Journal},
doi = {10.2139/ssrn.4028503},
url = {https://doi.org/10.2139/ssrn.4028503}
}RIS
TY - JOUR TI - Optimized Treatment of Refractory Hypercholesterolemia in Patients with Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia with Alirocumab (OPTIMIZE) AU - Isabella Sudano AU - François Mach AU - Tiziano Moccetti AU - Thilo Burkard AU - Christian Fahe AU - Alain Delabays AU - Hans Rickli AU - Pierre-Frédéric Keller AU - Jörn Dopheide AU - Sereina Bodenmann AU - Tom Fiolka AU - Georg Ehret AU - David Spirk PY - 2022 JO - SSRN Electronic Journal DO - 10.2139/ssrn.4028503 UR - https://doi.org/10.2139/ssrn.4028503 ER -
APA
Sudano, I., Mach, F., Moccetti, T., Burkard, T., Fahe, C., Delabays, A., Rickli, H., Keller, P., Dopheide, J., Bodenmann, S., Fiolka, T., Ehret, G., & Spirk, D. (2022). Optimized Treatment of Refractory Hypercholesterolemia in Patients with Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia with Alirocumab (OPTIMIZE). SSRN Electronic Journal. https://doi.org/10.2139/ssrn.4028503
Source records
- crossref · retrieved 2026-09-25T07:55:48.653Z